Literature DB >> 30766218

Prevalence of Hypogonadism in Low-Risk Prostate Cancer Survivors.

Lily Agrawal1, Rod Marianne Arceo-Mendoza1, Adrienne Barnosky1, Larissa Bresler1, Maguy Chiha1, Abigail Silva1, Cory Wilczynski1.   

Abstract

Increasing evidence, albeit small, suggests that testosterone replacement therapy can be cautiously considered in selected hypogonadal men treated with curative intent for low-risk prostate cancer and without evidence of active disease.

Entities:  

Year:  2016        PMID： 30766218      PMCID： PMC6375443     

Source DB:  PubMed          Journal:  Fed Pract        ISSN： 1078-4497


  37 in total

1.  Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.

Authors:  Ahmad Haider; Michael Zitzmann; Gheorghe Doros; Hendrik Isbarn; Peter Hammerer; Aksam Yassin
Journal:  J Urol       Date:  2014-06-26       Impact factor: 7.450

Review 2.  Testosterone therapy and cardiovascular risk: advances and controversies.

Authors:  Abraham Morgentaler; Martin M Miner; Monica Caliber; Andre T Guay; Mohit Khera; Abdulmaged M Traish
Journal:  Mayo Clin Proc       Date:  2015-02       Impact factor: 7.616

Review 3.  Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.

Authors:  Shalender Bhasin; Glenn R Cunningham; Frances J Hayes; Alvin M Matsumoto; Peter J Snyder; Ronald S Swerdloff; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2010-06       Impact factor: 5.958

Review 4.  Osteoporosis in men.

Authors:  E S Orwoll; R F Klein
Journal:  Endocr Rev       Date:  1995-02       Impact factor: 19.871

5.  Testosterone replacement therapy in the setting of prostate cancer treated with radiation.

Authors:  A W Pastuszak; A M Pearlman; G Godoy; B J Miles; L I Lipshultz; M Khera
Journal:  Int J Impot Res       Date:  2012-09-13       Impact factor: 2.896

6.  Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.

Authors:  Abraham Morgentaler; Ernani Luis Rhoden
Journal:  Urology       Date:  2006-12       Impact factor: 2.649

Review 7.  The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis.

Authors:  A A MacDonald; G P Herbison; M Showell; C M Farquhar
Journal:  Hum Reprod Update       Date:  2009-11-04       Impact factor: 15.610

8.  Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study.

Authors:  Frederick C W Wu; Abdelouahid Tajar; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe Casanueva; Gianni Forti; Aleksander Giwercman; Ilpo T Huhtaniemi; Krzysztof Kula; Margus Punab; Steven Boonen; Dirk Vanderschueren
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

9.  Effective testosterone suppression for prostate cancer: is there a best castration therapy?

Authors:  Leonard G Gomella
Journal:  Rev Urol       Date:  2009

10.  Long-term functional outcomes after treatment for localized prostate cancer.

Authors:  Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson
Journal:  N Engl J Med       Date:  2013-01-31       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.